Category: mcpwv

House 01, Hyde Park / Daffonchio & Associates Architects

first_imgPhotographs:  Adam LetchStructural Engineers:Hull Consulting EngineersLandscape Architect:Meleney’s GardensQuantity Surveyor:SM Schneid Quantity SurveyorsContractor:CTS ProjectsAuthor Of Text:Frances JoyntProject Team:Frances JoyntCity:SandtonCountry:South AfricaMore SpecsLess SpecsSave this picture!© Adam LetchRecommended ProductsDoorsdormakabaEntrance Doors – Revolving Door 4000 SeriesEnclosures / Double Skin FacadesAlucoilStructural Honeycomb Panels – LarcoreDoorsRabel Aluminium SystemsMinimal Sliding Door – Rabel 62 Slim Super ThermalMetallicsSculptformClick-on Battens in Ivanhoe ApartmentsText description provided by the architects. This house has been designed to be highly flexible and adapt to the owners’ changing needs. The house has two skins throughout: the sliding glass windows and doors, and the sliding timber shutters, which enable the owners to constantly transform the look and feel of the spaces to suit their activities, the weather and the time.Save this picture!First Floor PlanOn the ground floor, all of the doors in the living area can slide away to open out onto the expansive covered patio and garden, while the timber shutters set into the concrete portal on the south of the patio can slide away so that the patio is open to the landscaped motor court to the south, and to the garden and pool to the north. Along the full length of the northern facade on the first floor, folding stacking timber shutters outside the sliding windows provide shading and privacy for the bedrooms and TV room, but can be stacked open for extra sun and views.Save this picture!© Adam LetchThe generous internal volumes are accentuated by means of floor to ceiling glass doors and windows, internal pivot doors and cabinetry.Save this picture!© Adam LetchThe inclusion of a back of house kitchen, scullery and pantry enables the front kitchen in the open plan living area to remain uncluttered, with all appliances and utensils concealed, so that it reads as part of the tranquil living space rather than as a utility area.Save this picture!© Adam LetchThe use of raw, natural materials throughout the house, such as flamed granite floor tiles, wire brushed white oak, exposed off shutter concrete, stone cladding, and natural stone countertops and mosaics, impart a sense warmth, softness and comfort.Save this picture!© Adam LetchThe house is cooled by means of passive solar design, thermal mass, insulation, natural ventilation and cross ventilation. In winter, the house is heated with hot water under floor heating, connected to a heat pump (heat exchange). Domestic hot water is provided by means of solar geysers, and the pool is heated with solar mats.Project gallerySee allShow lessTicollage City / Costa Rica Pavilion at the Venice Biennale 2014Architecture NewsCritical Round-Up: The 2014 RIBA Stirling Prize ShortlistArchitecture News Share CopyHouses•Sandton, South Africa “COPY” “COPY” ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/527199/house-01-hyde-park-daffonchio-and-associates-architects Clipboard House 01, Hyde Park / Daffonchio & Associates ArchitectsSave this projectSaveHouse 01, Hyde Park / Daffonchio & Associates Architects Projects Architects: Daffonchio & Associates Architects Photographs House 01, Hyde Park / Daffonchio & Associates Architects ArchDaily South Africa Houses ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/527199/house-01-hyde-park-daffonchio-and-associates-architects Clipboard Save this picture!© Adam Letch+ 14 Share CopyAbout this officeDaffonchio & Associates ArchitectsOfficeFollowProductConcrete#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousesSandtonHousesSouth AfricaPublished on July 21, 2014Cite: “House 01, Hyde Park / Daffonchio & Associates Architects ” 21 Jul 2014. ArchDaily. Accessed 11 Jun 2021. ISSN 0719-8884Browse the CatalogPartitionsSkyfoldRetractable Walls – Stepped & Sloped SpacesVinyl Walls3MArchitectural Finishes DI-NOC in SkyPodsShowerhansgroheShowers – Croma EDoorsC.R. LaurenceMonterey Bi-Folding Glass Wall SystemTable LampsLouis PoulsenLamps – Panthella PortableBeams / PillarsLunawoodThermowood Frames and BearersSealantsEffisusMetal Roof Flashing – Stopper MRDropped CeilingsPure + FreeFormLinear Clip-Strip Ceiling SystemUrban ShadingPunto DesignPavilion – CUBEVentilated / Double Skin FacadeULMA Architectural SolutionsPaper Facade Panel in Nokia LibraryLouversAccoyaAccoya® Wood for Shutters and LouvresSpa / WellnessKlafsGyms & Relaxation RoomsMore products »Save世界上最受欢迎的建筑网站现已推出你的母语版本!想浏览ArchDaily中国吗?是否翻译成中文现有为你所在地区特制的网站?想浏览ArchDaily中国吗?Take me there »✖You’ve started following your first account!Did you know?You’ll now receive updates based on what you follow! Personalize your stream and start following your favorite authors, offices and users.Go to my streamlast_img read more

MESURA office / MESURA

first_imgManufacturers: Cortizo, BegurContractor:FonfasArchitect In Charge:Marcos PareraCity:BarcelonaCountry:SpainMore SpecsLess SpecsSave this picture!© Salva LópezRecommended ProductsDoorsECLISSESliding Pocket Door – ECLISSE LuceDoorsLonghiDoor – HeadlineLightsVibiaCeiling Lights – BIGPorcelain StonewareApavisaFloor Tiles – RegenerationA couple, a traditional house in the Empordà and one dream.Houses should evolve along with its users. Ana María and Manuel made the decision of spending as much time as possible in their summerhouse in Sant Mori, a rural village located between Figueres and Girona. Among forests and fields, this particular place offers their inhabitants the typical landscape of the Empordà. Save this picture!© Salva LópezThe objective was to recuperate the views lost in the small enlargement project and the old swimming pool area, taking profit of the stepped zone in the land slope. We had the opportunity to revitalize the noblest part of the area, and to give this place a different way of living with new exterior and interior limits and comfort parameters for this new period.Save this picture!© Salva LópezThe house had been designed to be used and enjoyed by one family during summer months and holidays. Up to now it was too big and impractical to live in during the whole year.MESURA’s proposal was to adapt the floor with access to the garden and restore an old and forgotten kitchen (as there was a bigger kitchen integrated in the noble floor), with the idea to transform it in the new heart of the building.Save this picture!© Salva LópezNEW SPACE – SAME IDENTITYCan Blasco-Nicolau, located in the historic old quarter of the medieval village of Sant Mori, had a large kitchen/dining room/living room area on the ground floor, which was used in the holiday period. Nevertheless, the existence of an old kitchen in this floor was the perfect opportunity in order to provide a more efficient use of this area and a new life to the building, in particular during cold winter months.Save this picture!© Salva LópezThe Project planned a complete rehabilitation of the kitchen with a total opening to the contiguous terrace and an additional covered opened area which was going to be used as daily dining room and small living room.The already special qualities of the building with its enormous personality have been maintained and strengthened. We could say that the new reform does not compete but improves its original identity. Save this picture!Floor PlanIn our first visit we discovered that the kitchen was closed to the exterior area (except for a small window) and covered by an excellent Catalan vault that rested on walls. Therefore, it was clear the need to open the kitchen with a new expansion that profited the vault and linked both rooms maintaining the typical structure of the house.Some years ago, in 1999, a small porch had been built. It had an unidirectional structure along the façade and it had been one of the most lived areas by the client in the hottest summer afternoons. This fact was relevant to us. It was important to strengthen this small area in order to build a new dining/living room interconnected with the porch and at the same time homogeneous to the garden.Save this picture!© Salva LópezFrom a structural and economic point of view, as well as from the environmental and visual impact (it is a protected house according to POUM in 2009, documented by the architect Amador Ferrer), this small intervention was an excellent solution because it didn’t incur in added volume but only redrew and completed its own irregular and fractured facade.Save this picture!SectionFollowing the line of the facade would let us profit an old pilaster (although its height was insufficient, 1,40m) and save on foundations considering the problems with the existing basement floor. In this way it was possible to build a roof without the need to place a pillar in a unidirectional structure (formed by one HEB-200), supported on the existing pilaster, and built with a concrete die to reach the minimum required height.Save this picture!© Salva LópezThis unidirectionality allowed us to reach a total flexibility in the roof nogging, with two differentiated levels: the first one at 2,20 m in order to reduce the access area and to find a more humane dimension for the dining room. The second one sought the maximum spatial spaciousness (3,5m) to have a skylight (luthern) and contact with the exterior.Consequently, the project was formalized thanks to its own structural response and therefore to the esthetical result.Save this picture!© Salva LópezBlasco-Nicolau Project is an effort to reduce to a minimum the strictly functional and structural aspects, with the objective to reach maximum spatial quality. The use of indoor areas with generous dimensions and opened to the landscape has let us improve its relationship with the environment and also experience a different relationship with Sant Mori’s natural surroundings.Project gallerySee allShow lessM-Apartments / PXParchitecture & Partners + David Garda Taller de ArquitecturaSelected ProjectsSusona Bodrum, LXR Hotels & Resorts / Gokhan AvciogluSelected Projects Share “COPY” 2016 Spain Photographs:  Salva López Manufacturers Brands with products used in this architecture project ArchDaily ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/797596/mesura-office-mesura Clipboard Year:  Houses Photographs Projects MESURA office / MESURASave this projectSaveMESURA office / MESURA Architects: MESURA Year Completion year of this architecture project CopyHouses, Extension•Barcelona, Spain “COPY” ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/797596/mesura-office-mesura Clipboard MESURA office / MESURA Save this picture!© Salva López+ 31 Share CopyAbout this officeMESURAOfficeFollowProductWood#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousesRefurbishmentExtensionBarcelonaSpainPublished on October 29, 2016Cite: “MESURA office / MESURA” 29 Oct 2016. ArchDaily. Accessed 11 Jun 2021. ISSN 0719-8884Browse the CatalogShowershansgroheShower MixersEducational3MProjection Screen Whiteboard FilmPartitionsSkyfoldWhere to Increase Flexibility in SchoolsLinoleum / Vinyl / Epoxy / UrethaneTerrazzo & MarbleTerrazzo in The Gateway ArchSkylightsLAMILUXGlass Skylight FE PassivhausConcreteKrytonSmart ConcreteMetallicsTrimoMetal Panels for Roofs – Trimoterm SNVWire MeshGKD Metal FabricsMetal Fabric in Kansas City University BuildingGlassDip-TechDigital Ceramic Curved Glass PrintingMetallicsRHEINZINKZinc Roof Systems – Double Lock Standing SeamChairs / StoolsFreifrauBarstool – OnaSealants / ProtectorsWoodenha IndustriesFireproofing System for Wood Cladding – BIME®More products »Save世界上最受欢迎的建筑网站现已推出你的母语版本!想浏览ArchDaily中国吗?是否翻译成中文现有为你所在地区特制的网站?想浏览ArchDaily中国吗?Take me there »✖You’ve started following your first account!Did you know?You’ll now receive updates based on what you follow! Personalize your stream and start following your favorite authors, offices and users.Go to my streamlast_img read more

VSO looks for fundraisers to work in Africa and Asia

first_img About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving. Tagged with: Recruitment / people Volunteering VSO looks for fundraisers to work in Africa and Asia AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis International development charity VSO is looking to send experienced fundraisers to work with local NGOs across Africa and Asia. It is holding an information day for managers and fundraisers on 20 October to give more details.VSO is looking in particular for fundraisers with at least two years experience, although fundraisers with additional skills could apply for short term assignments. Positions involve working alongside local staff, being paid local wage. Flights,accommodation and a range of support is offered. Advertisementcenter_img Howard Lake | 12 September 2007 | News The information day is followed by a Fundraisers Without Borders event, planned for November.  23 total views,  1 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThislast_img read more

Pay It Forward Day invites good deeds

first_img Tagged with: corporate Events Giving/Philanthropy AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis6 Today is Pay It Forward Day, on which individuals and businesses are encouraged to do a good deed for the day in return for good deeds received, thereby creating “a chain of positivity”.The Pay It Forward idea is simple: it involves passing on acts of kindness to others, often strangers, who then ‘pay it forward’ through their own act of kindness to another.The idea became the foundation of a movement in the USA with the Pay It Forward Foundation created in 2000 by Catherine Ryan Hyde, author of the 1999 book ‘Pay It Forward’, which has also been made into a film.Pay It Forward UK (PIF UK) is a not for profit initiative set up in 2012 by Becky Wells, who was invited to represent the movement on this side of the Atlantic after sharing her own experience online.Wells said:“What makes this form of charity so special is it’s not just about giving to someone else, but about them passing the good deed on and helping another person too. It’s a ripple effect made up of small deeds that can have a huge impact.” About Howard Lake Howard Lake is a digital fundraising entrepreneur. Publisher of UK Fundraising, the world’s first web resource for professional fundraisers, since 1994. Trainer and consultant in digital fundraising. Founder of Fundraising Camp and co-founder of GoodJobs.org.uk. Researching massive growth in giving. https://www.instagram.com/p/BEvEOcqL6x1/?taken-by=lpquk Pay It Forward Day invites good deeds Good deeds Jolly Good Causes, a press and communications agency specialising in helping small charities, is also involved. They are inviting large charities, businesses and individuals to contribute towards their Pay It Forward scheme by sponsoring one of their standalone services, which can then be claimed by any small charity in need of communications support. Advertisementcenter_img Howard Lake | 28 April 2016 | News PIF UK has suggested the following simple good deeds to do:If you’re buying takeaway food, grab an extra meal for someone homelessNext time you shop, pick up a couple of extra tins or some non-perishable goods to donate to your local food bankCooking a meal? Make an extra serving for an older neighbour or someone in need near you, or invite a lonely neighbour for lunchBecome a donor – give blood, or join a registerOffer your seat to someone on the bus, train or tubeWells added:“There are so many simple things each of us can do to make a difference to another person’s life. And when someone wants to repay you for a kindness you have done for them, just ask them to ‘pay it forward’ to someone else instead and help spread the kindness.” Restaurant chain Le Pain Quotidien is taking part in this year’s campaign. Throughout this week, when customers purchase their meal, they are invited to buy someone else a coffee, a tartine, a meal for two, or even a baking class. They can also donate £5 to Foodcycle for every baking class purchased as part of the scheme.  255 total views,  1 views today  256 total views,  2 views today AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to LinkedInLinkedInShare to EmailEmailShare to WhatsAppWhatsAppShare to MessengerMessengerShare to MoreAddThis6 Main image: heart of dominoes by Danm12 on Shutterstock.comlast_img read more

Journalist murdered in Sindh province

first_img Pakistani supreme court acquits main suspect in Daniel Pearl murder Reporters Without Borders today voiced revulsion at the murder of Nisar Ahmed Solangi, correspondent for the Sindhi-language newspaper, Khabroon, in Kingri, Sindh province.Ahmed Solangi, 34, died in a hail of nine bullets after he was ambushed by six people on motorbikes and armed with Kalashnikovs, who shot him at point blank range as he was distributing newspapers on 17 June.“We are shocked by the murder of Nisar Ahmed Solangi, less than three weeks after the killing of Noor Hakim, in the tribal areas on 2 June,” the worldwide press freedom organisation said. “The deteriorating working conditions and the insecurity facing journalists in the rural areas of the country are extremely worrying. It is crucial both that the local authorities find and punish the killers of Nisar Ahmed Solangi and that the Pakistani authorities put an end to this lawlessness”, the organisation said.Sindh’s rural areas are currently the scene of serious conflict between rival clans. A friend of the reporter, Khan Muhammad, told Reporters Without Borders, “Solangi received death threats two days previously, from a Sindhi tribe, Junejo, which was unhappy about his reports”. The journalist had written an article contesting allegations by Junejo members that a rival clan had killed some of its members in a recent clash. The journalist asserted that they had been killed by police officers.The family of the murdered journalist has begun legal proceedings against members of the Junejo clan: Hadu Junejo, Makal, Nazir, Ghulam Haiser, Siddiq and Nural.A reporter on Sindh TV News, Abdul Khaliq, dismissed a theory that Nisar Ahmed Solangi had been killed for ethnic reasons. “He was killed because of his profession,” the journalist said. PakistanAsia – Pacific Organisation Help by sharing this information April 21, 2021 Find out more RSF_en News News Pakistani journalist critical of the military wounded by gunfire Follow the news on Pakistan Pakistani TV anchor censored after denouncing violence against journalists January 28, 2021 Find out more to go further June 2, 2021 Find out more Reporters Without Borders urges the authorities to ensure a thorough investigation into the murder of Nisar Ahmed Solangi. “They must put an end to the lawlessness in rural areas where the bloodshed is escalating,” the organisation said. News June 20, 2007 – Updated on January 20, 2016 Journalist murdered in Sindh province Receive email alerts PakistanAsia – Pacific Newslast_img read more

Free legal clinic for low-income

first_imgLocal News WhatsApp Previous articleLaptop kiosk to be unveiledNext articleTEXAS VIEW: A national model for engaging school safety admin Pinterest Facebook By admin – March 17, 2018 Free legal clinic for low-income Facebookcenter_img Legal Aid of NorthWest TexasLegal Aid of NorthWest Texas, 620 N. Grant Ave., Suite 410, has scheduled a free evening legal clinic from 5:30 p.m. to 7 p.m. Tuesday.Low-income and low asset people needing legal advice in civil matters such as bankruptcy, consumer law, debt harassment and family law are welcome to attend.No criminal cases may be brought to the clinic. An appointment is required.For more information or to schedule an appointment, call Pete Fierro at 332-1207, ext. 4511. Twitter Legal Aid of NorthWest Texas.png Pinterest Twitter WhatsApplast_img read more

Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results

first_img Acquisition- and divestiture-related costs attributable to non-controlling interests Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results 1,228 Facebook (802 -3 WhatsApp 7 * 1 3,086 (3) (Loss) Income Before Taxes GAAP net (loss) income 1 % (2) Difference *The company does not have any non-GAAP adjustments to revenue. **EPS guidance for 2021 assumes a share count (assuming dilution) of approximately 2.53 billion shares. A reconciliation of anticipated 2021 GAAP EPS to non-GAAP EPS and the items excluded from non-GAAP EPS are provided in the table below. ) EPS − -4% -41 62 (4) Amount included in cost of sales represents a charge for the discontinuation of COVID-19 vaccine development programs. Amount included in research and development represents the charges of $2.7 billion for the acquisition of VelosBio Inc., $462 million for the acquisition of OncoImmune and $45 million for the discontinuation of COVID-19 vaccine development programs. 3Q 1,214 1.16 34 ProQuad / M-M-R II / Varivax 132 462 9,231 -5 698 63 462 Non-GAAP net income that excludes certain items 1,2 ** 3,350 1 2,792 4% 100 13,382 Livestock 16% $0.96 (0.83) GAAP TO NON-GAAP RECONCILIATION 6 ) − 72 270 % (916 140 $5,444 935 1,320 2 7 255 17% 156 71 47 Oncology Pipeline Highlights Merck continued to advance the development programs for KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy; Lynparza (olaparib), a PARP inhibitor being co-developed and co-commercialized with AstraZeneca; and Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor being co-developed and co-commercialized with Eisai Co., Ltd. (Eisai).Merck announced the following regulatory milestones for KEYTRUDA:Approval in the United States by the FDA in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 (Combined Positive Score [CPS]≥10), based on results from the KEYNOTE-355 study;Approval in the United States by the FDA of an expanded indication as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) based on the Phase 3 KEYNOTE-204 trial; and an updated pediatric indication for the treatment of pediatric patients with refractory cHL or cHL that has relapsed after two or more lines of therapy, both of which were previously approved under the FDA’s accelerated approval process;Filing acceptance with priority review by the FDA for a supplemental Biologics License Application (sBLA) for KEYTRUDA plus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer based on results from the KEYNOTE-590 study. A Prescription Drug User Fee Act (PDUFA) date is set for April 18, 2021;Filing acceptance in January 2021 by the FDA for an sBLA seeking use of KEYTRUDA for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation based on the results of the KEYNOTE-629 trial. The FDA has set a PDUFA date of Sept. 9, 2021; andApproval in January 2021 in the European Union for KEYTRUDA as first-line treatment in adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer based on results from the KEYNOTE-177 study. -7 Arcoxia Other Pipeline HighlightsIn January 2021, Merck announced approval in the United States by the FDA of Verquvo (vericiguat), a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%, based on the results of the Phase 3 VICTORIA trial. Verquvo is being jointly developed with Bayer AG.In January 2021, Merck announced filing acceptance with priority review by the FDA of a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine for use in adults 18 years of age and older. A PDUFA date is set for July 18, 2021. Previously, Merck also announced the submission of an application for V114 to the European Medicines Agency.Merck announced that two Phase 3 adult studies (the PNEU-PATH [V114-016] and PNEU-DAY [V114-017] trials), evaluating the safety, tolerability and immunogenicity of V114, each met their primary immunogenicity objectives.Merck presented Week 96 data from the Phase 2b trial (NCT03272347) that showed islatravir, the company’s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (PIFELTRO), maintained viral suppression in treatment-naïve adults with HIV-1 infection.Merck announced a collaboration with the Bill & Melinda Gates Foundation where the foundation will provide funding to support the Phase 3 IMPOWER 22 trial evaluating the safety and efficacy of investigational islatravir for both treatment and prevention in women and adolescent girls at high-risk for acquiring HIV-1 infection in sub-Saharan Africa.Merck also announced plans to conduct additional studies in HIV prevention with investigational islatravir including IMPOWER 24, a global Phase 3 clinical trial to evaluate islatravir as a once-monthly oral agent for pre-exposure prophylaxis (PrEP) at sites across the world and among other key populations impacted by the epidemic, including men who have sex with men and transgender women.In January 2021, Merck announced interim data from the Phase 2a trial (NCT04003103) in adults evaluating the safety, tolerability and pharmacokinetics (PK) of the investigational once-monthly oral islatravir tablet for PrEP. Interim findings demonstrated that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the two doses studied (60 mg and 120 mg).Merck continued to advance MK-8507, the company’s investigational once-weekly oral non-nucleoside reverse transcriptase inhibitor (NNRTI). The company presented results from Phase 1/1b studies that supported further investigation for once-weekly oral administration as part of combination antiretroviral therapy. Enrollment in a Phase 2 trial evaluating a switch to islatravir and MK-8507 once weekly in adult participants with HIV-1 who have been virologically suppressed for ≥6 months on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) once-daily, is currently ongoing. Business DevelopmentIn December 2020, Merck acquired VelosBio, a privately held, clinical-stage biopharmaceutical company, to strengthen Merck’s oncology pipeline with MK-2140 (formerly known as VLS-101), an investigational antibody-drug conjugate to treat hematological malignancies and solid tumors. Fourth-Quarter and Full-Year Financial Impact of COVID-19 In the fourth quarter, the estimated negative impact of the COVID-19 pandemic to Merck’s pharmaceutical revenue was approximately $400 million. As expected, within the company’s human health business, revenue was negatively impacted by reduced access to health care providers given social distancing measures, which negatively affected vaccine sales in particular. Operating expenses were positively impacted in the fourth quarter by approximately $50 million, primarily driven by lower promotional and selling costs, partially offset by higher research and development (R&D) expenses, net of investments in COVID-19-related antiviral and vaccine research programs. The estimated overall negative impact of the COVID-19 pandemic to Merck’s revenue for the full year 2020 was approximately $2.5 billion, largely attributable to the human health business but including approximately $50 million attributable to Animal Health. Operating expenses for the full year were positively impacted by approximately $600 million, primarily driven by lower promotional and selling costs, as well as lower R&D expenses, net of investments in COVID-19-related antiviral and vaccine research programs. Fourth-Quarter and Full-Year Revenue Performance The following table reflects sales of the company’s top pharmaceutical products, as well as sales of animal health products. 6% Fourth Quarter Tax Rate 2020 GAAP EPS ) 273 -14% $7,067 ) Net (Loss) Income Attributable to Merck & Co., Inc. Total Sales 128 $11,868 64 481 185 − 2% 11,464 28 299 Total acquisition- and divestiture-related costs 8% 6% Selling, general and administrative 152 98 9 ) 3,993 -6% 926 2,540 -20 2.15 2,888 Full Year2019 797 -5% $5.52 to $5.72 287 84 (258 ANIMAL HEALTH -4% 580 Other (income) expense, net 10 Cost of sales (3 Other acquisition- and divestiture-related costs 3 ) 3,737 5% Janumet PROQUAD, M-M-R II and VARIVAX 53 $1.16 ) 1% 1,418 10,468 -17% 88 43,021 355 1,878 62 Net decrease (increase) in income before taxes 176 320 -29 206 PNEUMOVAX 23 − Net Income Attributable to Merck & Co., Inc. Twitter 0% -28% (0.15 5 Amount for full-year 2020 includes $826 million related to collaborations with Seagen, Inc. 83 671 4,327 -20 696 -34 (3,357 50 2020 1% **Refer to table on page 12. 237 4 Only the line items that are affected by non-GAAP adjustments are shown. Pinterest 3,350 Nom % 2,939 Other Pharmaceutical (7) ) 9 175 2,269 (223) $11,735 3,111 63% 62% − $5.94 57 % 4% 496 -27 – Virology 578 43% ) 139 2020 4 787 (3) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. -38 Lenvima* 15,097 305 53 26% Merck announced that the FDA’s Oncologic Drugs Advisory Committee will discuss Merck’s application for KEYTRUDA for the treatment of patients with high-risk, early-stage triple-negative breast cancer based on the results from the Phase 3 KEYNOTE-522 study. The meeting will be held on Feb. 9, 2021.Merck’s Phase 3 KEYNOTE-122 trial evaluating KEYTRUDA versus standard of care (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer (NPC) did not meet its primary endpoint of overall survival (OS). Full results will be presented at a future medical meeting.Merck and Eisai announced the Phase 3 KEYNOTE-581/CLEAR trial (Study 307) met its primary endpoint of progression free survival (PFS) and its key secondary endpoints of OS and objective response rate (ORR) for KEYTRUDA plus Lenvima as a first-line treatment for patients with advanced renal cell carcinoma (RCC). In a second arm of the trial, Lenvima plus everolimus also met the trial’s primary endpoint of OS and the key secondary endpoint of ORR as a first-line treatment for patients with advanced RCC. Full results from the trial will be presented at the 2021 Genitourinary Cancers Symposium (ASCO GU) on Feb. 13, 2021.Merck and Eisai announced the Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA and Lenvima met its dual primary endpoints of OS and PFS and its secondary endpoint of ORR in patients with advanced endometrial cancer following at least one prior platinum-based regimen.Merck and AstraZeneca announced two European Union approvals of Lynparza:As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA 1/2 mutations (germline and/or somatic) who have progressed following a prior therapy that included a new hormonal agent; andAs first-line maintenance treatment in combination with bevacizumab for adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a breast susceptibility gene 1/2 ( BRCA 1/2) mutation and/or genomic instability. 75 638 297 213 10,615 503 2Q 44 130 3,161 88 Table 1 313 404 ) 2% (180) Alliance Revenue – Lenvima (2) Effective tax rate 6% (3 $15,485 * $ -110 -13 -13 Cost of sales Non-GAAP net income that excludes items listed below 1,2 ) Other Revenues** ROTATEQ 9% Income tax (benefit) expense 6 Livestock 270 Simponi 46 47 (UNAUDITED) (8,015 345 Table 2b 838 404 830 59 53 $12 258 -14 $260 533 9% 39 $2,357 $ − 886 $46,840 47 $ in millions, except EPS amounts 2 31 196 − Nom % 648 Restructuring costs 15.3 5% Other (income) expense, net (7) Includes Pharmaceutical products not individually shown above. $ ) 2 (883 − * 8,730 $325 Research and development − 605 Selling, general and administrative 74 % 1 − 700 10% $47,994 * 13% 838 2,371 6 Primaxin − GAAP EPS (5,444 9,843 178 -5.0 1,976 − (4) Alliance Revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. (193) Restructuring costs 2,548 251 $3,254 285 (916) Non-GAAP2 139 83 72 794 (AMOUNTS IN MILLIONS) Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. 132 ) -8 -1 − 0.92 (423 -2 -20 66 -9 1.32 19.4 ) 2 249 − -7 -70 935 2,548 − (20) 55 (3.16 3.81 145 339 50 1,764 -19 Selling, general and administrative GAAPAcquisition andDivestiture-RelatedCosts (1)RestructuringCosts (2)Certain OtherItems (4)AdjustmentSubtotalNon-GAAP -17 576 Non-GAAP2 32 Research and development $ Selling, general and administrative (1) (89) 50 142 241 60 165 4,243 1% 39 116 (886) 926 (1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details. 3 (200) -1 662 53% Decrease (Increase) in Net Income Due to Excluded Items: 1% 50 2 (8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. * 3,086 43 223 $2.78 ) 3,153 (2,153 193 530 * 100% or greater 9,872 -42 210 % Change 3.81 791 211 $(2,094) 11 503 − JANUVIA / JANUMET 1% 758 8,015 3,539 -14 -42 $2,978 9,486 71 693 (3,033 Income Tax Provision (Benefit) (3 211 $705 Research and development 1,101 993 2,095 260 1 5 82 3,704 Cubicin Restructuring costs 379 2,939 10,468 927 $11,760 183 − 2,660 EPS** 91 Vaqta 2,800 462 − 374 223 $51.8 to $53.8 billion ) 1,131 206 205 (886 1,076 -7% 4Q20 Revenue 11 982 44 195 2019 (1,730 13 109 1,328 189 801 Change 4,709 *Alliance revenue for these products represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. **Other revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. The revenue hedging activities resulted in negative revenue in the fourth quarter of 2020. Pharmaceutical Revenue Fourth-quarter pharmaceutical sales increased 8% to $11.4 billion. Excluding the favorable effect from foreign exchange, sales grew 6%. The increase was driven by growth in oncology, vaccines, reflecting the replenishment of GARDASIL 9 doses previously borrowed from the U.S. Centers for Disease Control and Prevention (CDC) Pediatric Vaccine Stockpile as discussed below, and hospital acute care, partially offset by the negative impact of the COVID-19 pandemic and the ongoing impacts of the loss of market exclusivity for several products. Growth in oncology was largely driven by sales of KEYTRUDA, which were $4.0 billion for the quarter. Global sales growth of KEYTRUDA reflects continued strong momentum from the non-small-cell lung cancer indications as well as continued uptake in other indications, including adjuvant melanoma, RCC, bladder, head and neck squamous cell carcinoma (HNSCC) and MSI-H cancers, as well as uptake following the recent launch of the 400mg every 6 week adult dosing regimen in the U.S., partially offset by the negative impacts of the COVID-19 pandemic and pricing in Japan. Also contributing to growth in oncology was higher alliance revenue related to Lynparza and Lenvima reflecting continued uptake in approved indications in the U.S., Europe and China. Growth in vaccines for the fourth quarter was driven by higher sales of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] and GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). Fourth-quarter 2020 GARDASIL 9 sales were increased by $120 million due to the replenishment of doses that were borrowed in the fourth quarter of 2019 from the CDC Pediatric Vaccine Stockpile. GARDASIL 9 sales in the fourth quarter of 2019 were decreased by $120 million due to the borrowing. GARDASIL/GARDASIL 9 sales growth also reflects higher demand in China. Growth was partially offset by the negative impact of the COVID-19 pandemic globally. Excluding the borrowing-related activity in both periods, GARDASIL/GARDASIL 9 sales grew 8% in the quarter, or 6% excluding the favorable impact from foreign exchange. Growth in hospital acute care reflects higher demand globally for BRIDION (sugammadex) Injection 100 mg/mL, a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults undergoing surgery; and the continued uptake of PREVYMIS (letermovir), a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant. Pharmaceutical sales in the quarter were negatively affected by the ongoing impacts from the loss of market exclusivity, including for NUVARING (etonogestrel/ethinyl estradiol vaginal ring), ZETIA (ezetimibe) and certain products in diversified brands. In addition, the decline in sales of JANUVIA (sitagliptin) and JANUMET (sitagliptin and metformin HCI) reflects continued pricing pressure in the United States, which more than offset higher demand in certain international markets. Full-year 2020 pharmaceutical sales increased 3% to $43.0 billion; excluding the unfavorable effect from foreign exchange, sales grew 4%, primarily due to higher sales in oncology, reflecting strong growth in KEYTRUDA, higher sales of certain vaccines including PNEUMOVAX 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease, and higher sales of certain hospital acute care products, including PREVYMIS and BRIDION. As discussed above, the COVID-19 pandemic negatively affected sales in 2020. Also negatively affecting sales in 2020 was the ongoing impacts of the loss of market exclusivity for several products, lower sales of pediatric vaccines, as well as pricing pressure in diabetes. Animal Health Revenue Animal Health sales totaled $1.2 billion for the fourth quarter of 2020, an increase of 4% compared with the fourth quarter of 2019; excluding the unfavorable effect from foreign exchange, Animal Health sales grew 6%. Growth in the quarter reflects a net favorable impact of one-time items, including an additional month of sales in the current quarter related to the 2019 acquisition of Antelliq Corporation (Antelliq), partially offset by distributor purchasing patterns. Also contributing to growth were contributions from smaller acquisitions, as well as the underlying performance of the business driven by companion animal products, reflecting higher demand in companion animal vaccines and parasiticides. Worldwide sales for the full year of 2020 were $4.7 billion, an increase of 7%; excluding the unfavorable effect from foreign exchange, sales grew 10%. Full-year sales growth was primarily driven by livestock sales which included an additional five months of sales in the year related to the 2019 acquisition of Antelliq, along with higher sales of companion animal products, primarily the BRAVECTO (fluralaner) line of products for parasitic control, and companion animal vaccines. Fourth-Quarter and Full-Year Expense, EPS and Related Information The tables below present selected expense information. Decrease (increase) in net income Emend (1,055) $12,332 78 $1,594 * Other (income) expense, net 3Q (21) 43 Year Ended $8,015 Higher than 2020 by a high-single to low-double-digit rate 43 55 2019 158 190 Zetia 3,669 309 2,888 2,784 4 15% to 16% Selling, general and administrative -18 Dec. 31,2019 4 998 7,067 GAAP EPS 411 Difference 71 2% 238 Acquisition- and divestiture-related costs (5 498 857 3 − Cost of sales 88 Estimated income tax (benefit) expense Atozet (4,180 30 Organon Update Merck expects the spinoff of Organon to be completed late in the second quarter of 2021. The transaction is expected to create two companies with enhanced strategic and operational focus, improved agility, simplified operating models, optimized capital structures and improved financial profiles. Merck believes the transaction will deliver significant benefits for both Merck and Organon and create value for Merck shareholders. In 2020, the products that will comprise Organon achieved revenues of $6.5 billion. In 2021, assuming it operated as an independent company for the full year, Organon is expected to generate $6.0 billion to $6.5 billion in revenue. As it nears the end of loss of exclusivity exposure to key brands, Organon will be well positioned for growth led by its Women’s Health and Biosimilars portfolios, with expected low to mid-single digit annual revenue growth off of a 2021 base year. As a standalone company post spinoff, Organon anticipates having non-GAAP operating margins in the mid-30% range. This compares to a non-GAAP operating margin of approximately 45% within Merck, with the difference reflecting additional costs Organon will incur to operate as an independent company. Earnings before interest, taxes, depreciation and amortization (EBITDA) margins are anticipated in the high 30% range post spinoff. Organon’s operating and EBITDA margins are expected to increase over time. At this time, Organon is expected to have $9.0 billion to $9.5 billion in initial debt and is expected to pay a special tax-free dividend to Merck of approximately $8.5 billion to $9.0 billion. The remaining cash, as well as ongoing cash flows from operations, is expected to provide the company with ample cash flow and financial flexibility for potential business development opportunities, debt paydown and a meaningful dividend that will be incremental to the dividend Merck currently pays its shareholders. Actual debt balances will be determined based on market conditions and desired bond rating. For Merck, the spinoff of Organon will allow it to increase focus on key growth pillars, result in higher revenue and EPS growth rates and enable incremental operating efficiencies of approximately $1.5 billion which are expected to be achieved ratably over three years, with approximately $500 million reflected in Merck’s 2021 financial outlook. Merck will continue to incur overhead costs previously allocated to the Organon products, which are estimated to be approximately $400 million on a full-year basis. These costs are expected to be reduced over time and are netted into the overall efficiency target. In addition, the special tax-free dividend from Organon will be allocated to business development or share repurchase. As a result of stronger growth Organon is expected to achieve as a standalone company, combined with the benefit of operating efficiencies at Merck enabled by the spinoff, Merck expects combined non-GAAP EPS of the two companies to be higher within 12-24 months post-spinoff versus what would have been achieved assuming no transaction. Merck will host an investor event prior to the completion of the spinoff at which time Organon management will present its strategy, opportunities for growth and financial outlook. Further details will be announced at a future date. Earnings Conference Call Investors, journalists and the general public may access a live audio webcast of the call today at 8:00 a.m. EST on Merck’s website at https://www.merck.com/investor-relations/events-and-presentations/. Institutional investors and analysts can participate in the call by dialing (833) 353-0277 or (469) 886-1947 and using ID code number 2268598. Members of the media are invited to monitor the call by dialing (833) 353-0277 or (469) 886-1947 and using ID code number 2268598. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call. About Merck For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www.sec.gov ). $2,126 Restructuring costs $6.48 to $6.68 ) 3,161 28% ) WhatsApp -18 5% 281 GAAP % GAAP 60 Alliance Revenue – Lynparza (2) (1.65 355 $46,840 Net Income (1,028) $ -25% -27% Only the line items that are affected by non-GAAP adjustments are shown. 5,950 $3,373 196 *Greater than 100%. Full Year Dec. 31,2020 Decrease (increase) in net income 103 Cost of sales (1) (223 165 132 4 Fourth-quarter and full-year 2020 include a $1.6 billion impairment charge related to ZERBAXA. Full-year 2019 includes a $612 million impairment charge related to SIVEXTRO (tedizolid phosphate). 330 14,112 4Q -20% 777 Other (income) expense, net Charge for the acquisition of OncoImmune 675 821 (3 102 (61 4 123 43 13% -1 13,558 4,393 (0.83 11,084 -50 (357 15.5 1,194 124 386 $251 1 GAAP TO NON-GAAP RECONCILIATION $175 (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related costs also includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition. ) 5,532 ) -27 117 9 5,532 11,084 13,558 3,737 $12,514 * 9% MERCK & CO., INC. 8,791 CONSOLIDATED STATEMENT OF INCOME – GAAP 41 % KEYTRUDA 99 797 % 117 Local NewsBusiness (2,092 1,168 Research and development % 45 Other (income) expense, net Year Ended % 309 2 1,709 View source version on businesswire.com:https://www.businesswire.com/news/home/20210204005437/en/ CONTACT: Media Contact:Patrick Ryan (973) 275-7075Investor Contacts:Peter Dannenbaum (908) 740-1037Michael DeCarbo (908) 740-1807 KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: ONCOLOGY HEALTH INFECTIOUS DISEASES CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Merck & Co., Inc. Copyright Business Wire 2021. PUB: 02/04/2021 06:45 AM/DISC: 02/04/2021 06:45 AM http://www.businesswire.com/news/home/20210204005437/en % Change 4,703 4% 2,357 70 2,275 52 * Bridion 68 257 -4 -5.0 (21) 11,367 -34 113 -33 578 Dec. 31,2019 199 3 4Q 39 57 % -9 -13% 98 TOTAL SALES (1) Lynparza* Charge for the acquisition of Peloton Therapeutics, Inc. $12,551 % 1,186 GARDASIL / GARDASIL 9 (2.15 83 11 168 (3,704 1.38 453 345 Difference Year Ended Dec. 31, 2020 2,789 89 97 3.16 − 482 ) 55 $ 578 1,855 993 -40 IMPLANON / NEXPLANON -56 8 Fourth Quarter Other Revenues (8) 287 774 ) (357 GAAP Year Ended $ 16 6% 16 67 151 1,149 Income Tax Provision (1) $12,514 Research and development (1) -45% Charge for the acquisition of VelosBio ) 5 $5,532 -20 ) $2,900 ) (258 Pneumovax 23 − 375 ) 10% -14 -24 195 (3,418 Restructuring costs 35 218 Sales 17,861 67 2,559 ) -27 (3,357 55 48 (3 2,784 146 $ in millions (5,950 ) 10,533 115 -63 8,791 309 10,460 -28 67 0.92 13 By Digital AIM Web Support – February 4, 2021 462 (2) Represents separation and other related costs associated with restructuring activities under the company’s formal restructuring programs. (81 46,840 Net (Loss) Income Attributable to Merck & Co., Inc. 30 (1,055 -14% GAAP net (loss) income 1 (1) Amount included in cost of sales primarily reflects a $1.6 billion intangible asset impairment charge related to ZERBAXA and $1.1 billion for the amortization of intangible assets recognized as a result of business acquisitions. Amount included in selling, general and administrative expenses reflects $710 million related to the company’s planned spin-off of Organon & Co., approximately $95 million of costs related to the acquisition of ArQule, Inc., and other acquisition and divestiture-related costs. Amount included in other (income) expense, net, primarily reflects expenses related to an increase in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. MERCK & CO., INC. 5 (20) 1 ) 2020 (1.32 58 725 1,168 Follistim AQ 211 726 (0.68 63 62 204 83 378 285 2,541 $15,082 1 75 $ (5,444 (20 10,455 $ 103 3,190 * Women’s Health 172 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) 145 2,275 GAAPAcquisition andDivestiture-RelatedCosts (1)RestructuringCosts (2)Certain OtherItems (4)AdjustmentSubtotalNon-GAAP Cost of sales $1,609 – Dec. 31,2020 62 97 SIMPONI 16 3% -12 209 14% 15,485 214 1,025 ) 623 Acquisition- andDivestiture-Related Costs3,4 2,357 Noxafil Companion Animals $ 490 − 578 % 41,751 Other (income) expense, net 824 ) (303 57 908 76 Income Before Taxes ) 60 (2,094) (1) Amount included in cost of sales primarily reflects a $1.6 billion intangible asset impairment charge related to ZERBAXA and $274 million for the amortization of intangible assets recognized as a result of business acquisitions. Amount included in selling, general and administrative expenses reflects $244 million related to the company’s planned spin-off of Organon & Co., and other acquisition and divestiture-related costs. 16% 155 73 (4,483 5,276 2.78 ) 975 1Q $5.19 (671 Diversified Brands 2 Merck is providing certain 2020 and 2019 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the items, see Tables 2a and 2b attached to this release. RestructuringCosts ) 680 Keytruda 103 241 Full-Year 2021 2,681 227 -20 ) Implanon / Nexplanon Net Income (6) 5 18 -28 10,468 (4,180 Cozaar / Hyzaar 5,838 -11 Prevymis $44 3,715 -73 -14% (3) Total Vaccines sales were $2,155 million, $1,418 million, $2,521 million and $2,163 million in the first, second, third and fourth quarters of 2020 and $1,887 million, $2,037 million, $2,517 million and $1,928 million in the first, second, third and fourth quarters of 2019, respectively. 388 RestructuringCosts 57 506 53 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) Earnings per Common Share Assuming Dilution -11% % Change (Loss) Earnings per Common Share Assuming Dilution Net (Loss) Income -11 37 4Q19 ) Year Ended Dec. 31, 2019 2,978 58 5.94 $ 5% ) 147 638 (4) The effective income tax rates for the fourth quarter and the full year of 2020 include the unfavorable impact of charges for the acquisitions of VelosBio Inc. and OncoImmune for which no tax benefits were recognized. The effective income tax rates for the fourth quarter and the full year of 2019 include the unfavorable impact of a charge for the acquisition of Peloton Therapeutics, Inc. for which no tax benefit was recognized and the favorable impact of product mix. The effective income tax rate for the full year of 2019 also reflects a net tax benefit of $364 million related to the settlement of certain federal income tax matters. ) 7 16 Dec. 31,2019 42 Animal Health Operating expenses $260 Other Table 3 0.24 2019 998 -36 $ in millions, except EPS amounts 777 10,615 7,082 Full Year $10,816 4 (506) 4Q ChangeEx-Exchange 329 Ex-Exch% 32 Ex-Exch% 94 $0.92 $10,872 (379 2,718 $47,994 58 208 ) -20 $46,840 857 1,198 453 $621 PHARMACEUTICAL 3,373 ) 1 Net (loss) income attributable to Merck & Co., Inc. Selling, general and administrative 1,082 -11 11% ) 63 GAAP (generally accepted accounting principles) (loss) earnings per share assuming dilution (EPS) was $(0.83) for the fourth quarter and $2.78 for the full year of 2020. Non-GAAP EPS was $1.32 for the fourth quarter and $5.94 for the full year of 2020. GAAP EPS for the fourth quarter and full year of 2020 reflect a $2.7 billion charge for the acquisition of VelosBio Inc. (VelosBio). The fourth quarter and full year of 2020 also include a $1.6 billion pretax intangible asset impairment charge related to ZERBAXA (ceftolozane and tazobactam), resulting from a recall in December 2020 and a temporary suspension of sales which reduced expected future cash flows of this product. In addition, the full year of 2020 reflects pretax charges of $1.1 billion related to certain license and collaboration agreements. Non-GAAP EPS excludes the charges noted above, other acquisition- and divestiture-related costs, restructuring costs and certain other items. Refer to the GAAP to non-GAAP reconciliation table on page 12 for further details. COVID-19 Research Highlights Building on the company’s experience with antivirals, Merck advanced its scientific programs in an effort to help combat SARS-CoV-2, specifically:Molnupiravir (also known as MK-4482) – Merck continued the clinical development of molnupiravir, an orally available antiviral candidate for the treatment of COVID-19, in collaboration with Ridgeback Biotherapeutics LP. It is currently being evaluated in Phase 2/3 clinical trials in both the hospital and outpatient settings. The primary completion date for the Phase 2/3 studies is May 2021. The company anticipates interim efficacy data in the first quarter of 2021.MK-7110 (also known as CD24Fc) – In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, to accelerate the development of MK-7110, a therapeutic candidate for the treatment of patients with severe and critical COVID-19.In December 2020, Merck entered into a supply agreement with the U.S. government to support the development, manufacture and initial distribution of MK-7110 upon approval or Emergency Use Authorization from the U.S. Food and Drug Administration (FDA).Topline results from a pre-planned interim efficacy analysis from a Phase 3 study of MK-7110 were released in Sept. 2020. Full study results are expected in the first quarter of 2021. 8 − 1,878 1,097 3,284 444 $ in millions 1,971 27 696 14,380 414 1,709 1,122 $5.52 to $5.72 $ 578 -110% 30% 13,558 488 5,838 57 114 7% 693 621 11,095 -16 Non-GAAP EPS that excludes items listed below 2 196 56 Change Ex-Exchange $ 177 374 41 -17 4 GAAP − 74 293 Cost of sales -62 580 28 49 475 $ 2,634 12,514 (253) 6 Includes the estimated tax impact on the reconciling items. Amount for full-year 2020 includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 acquisition of Cubist Pharmaceuticals, Inc. Amount for full-year 2019 includes a $364 million net tax benefit related to the settlement of certain federal income tax matters, an $86 million tax benefit related to the reversal of tax reserves established in conjunction with the divestiture of Merck’s Consumer Care business in 2014 as a result of the lapse in the statute of limitations, and a $117 million tax charge related to the finalization of treasury regulations associated with the 2017 enactment of U.S. tax legislation. 13 (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company’s formal restructuring programs. 1,183 ) 7 160 Fourth-Quarter 2020 -42 3 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a result of acquisitions and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other costs related to business acquisitions and divestitures. (5) Net product sales in Merck’s marketing territories. -20 -24% Nasonex % 30% − (6) Total Diabetes sales were $1,353 million, $1,418 million, $1,405 million and $1,412 million in the first, second, third and fourth quarters of 2020 and $1,402 million, $1,480 million, $1,360 million and $1,472 million in the first, second, third and fourth quarters of 2019, respectively. 739 Invanz GAAP 4% Fourth-Quarter 2019 $ in millions Remicade Restructuring costs $11,868 211 9,777 1Q 123 $ 488 ) -18 43,021 15% to 16% 213 1,198 (Gains) losses on investments in equity securities 2,648 -17 2,159 GAAP Expense, EPS and Related Information Gross margin was 55.8% for the fourth quarter of 2020 compared to 69.1% for the fourth quarter of 2019. The decrease reflects higher acquisition- and divestiture-related costs, including an impairment charge related to ZERBAXA, a charge related to the discontinuation of COVID-19 vaccine development programs, higher inventory write-offs due to a recall of ZERBAXA, pricing pressure and foreign exchange, partially offset by the favorable effects of product mix and manufacturing variances. Gross margin was 67.7% for the full year of 2020 compared to 69.9% for the full year of 2019. The decrease in gross margin for the full year of 2020 reflects higher acquisition- and divestiture-related costs, including an impairment charge related to ZERBAXA, pricing pressure, a charge related to the discontinuation of COVID-19 vaccine development programs, higher amortization of intangible assets related to collaborations, and higher inventory write-offs, partially offset by the favorable effects of product mix and lower restructuring costs. Selling, general and administrative expenses were $3.1 billion in the fourth quarter of 2020, an increase of 7% compared to the fourth quarter of 2019. The increase was largely driven by higher acquisition- and divestiture-related costs, primarily reflecting costs related to the company’s planned spinoff of Organon & Co. (Organon), as well as a $100 million contribution to the Merck Foundation to support philanthropic programs and initiatives that help address health disparities and strengthen communities in the U.S. and around the world; partially offset by lower selling and administrative costs, including less travel and meeting expenses, due in part to the COVID-19 pandemic. Full-year 2020 selling, general and administrative expenses were $10.5 billion, a decrease of 1% compared to the full year of 2019. The decrease primarily reflects lower administrative, selling and promotional costs, due in part to the COVID-19 pandemic, largely offset by higher acquisition- and divestiture-related costs, primarily reflecting costs related to the company’s planned spinoff of Organon. R&D expenses were $5.8 billion in the fourth quarter of 2020, compared with $2.5 billion in the fourth quarter of 2019. R&D expenses were $13.6 billion for the full year of 2020, a 37% increase compared to the full year of 2019. The increase in both periods was primarily driven by higher upfront payments for acquisitions and collaborations, including a $2.7 billion charge in 2020 for the acquisition of VelosBio. In addition, the increase in both periods reflects higher expenses related to clinical development and increased investment in discovery research and early drug development. These increases were partially offset by lower travel and meeting expenses due to the COVID-19 pandemic, as well as lower acquisition- and divestiture-related costs. Other (income) expense, net, was $258 million of income in the fourth quarter of 2020 compared to $223 million of income in the fourth quarter of 2019, primarily reflecting higher income from investments in equity securities, net, which was $375 million in 2020 compared with $119 million in 2019, largely from the recognition of unrealized gains on securities. Other (income) expense, net, was $886 million of income for the full year of 2020 compared to $139 million of expense for the full year of 2019, primarily reflecting higher income from investments in equity securities, net, which was $1.3 billion in 2020 compared with $170 million in 2019, largely from the recognition of unrealized gains on securities. The effective income tax rates were (5.0)% for the fourth quarter and 19.4% for the full year of 2020. The effective income tax rates for the fourth quarter and full year of 2020 reflect the unfavorable impact of the charge for the acquisition of VelosBio for which no tax benefit was recognized. GAAP EPS was $(0.83) for the fourth quarter of 2020 compared with $0.92 for the fourth quarter of 2019. GAAP EPS was $2.78 for the full year of 2020 compared with $3.81 for the full year of 2019. Non-GAAP Expense, EPS and Related Information Non-GAAP gross margin was 73.0% for the fourth quarter of 2020 compared to 72.6% for the fourth quarter of 2019. The increase in the fourth quarter reflects the favorable effects of product mix and manufacturing variances, partially offset by higher inventory write-offs due to a recall of ZERBAXA, pricing pressure and foreign exchange. Non-GAAP gross margin was 74.3% for the full year of 2020 compared to 74.9% for the full year of 2019. The decrease reflects pricing pressure, higher amortization of intangible assets related to collaborations and higher inventory write-offs, partially offset by the favorable effect of product mix. Non-GAAP selling, general and administrative expenses were $2.8 billion in the fourth quarter of 2020, a decrease of 2% compared to the fourth quarter of 2019. Full-year 2020 non-GAAP selling, general and administrative expenses were $9.5 billion, a decrease of 9% compared to the full year of 2019. The decrease in both periods primarily reflects lower administrative and selling costs, including less travel and meeting expenses, due in part to the COVID-19 pandemic. The declines were partially offset by the contribution to the Merck Foundation. Non-GAAP R&D expenses were $2.6 billion in the fourth quarter of 2020, a 12% increase compared to the fourth quarter of 2019. Non-GAAP R&D expenses were $9.2 billion for the full year of 2020, a 6% increase compared to the full year of 2019. The increase in both periods was primarily driven by higher expenses related to clinical development and increased investment in discovery research and early drug development, partially offset by lower travel and meeting expenses due to the COVID-19 pandemic. Non-GAAP other (income) expense, net, was $253 million of income in the fourth quarter of 2020 compared to $193 million of income in the fourth quarter of 2019, primarily reflecting higher income from investments in equity securities, net, which was $375 million in 2020 compared with $119 million in 2019, largely from the recognition of unrealized gains on securities. Non-GAAP other (income) expense, net, for the full year of 2020 was $916 million of income compared to $200 million of income for the full year of 2019, primarily driven by higher income from investments in equity securities, net, which was $1.3 billion in 2020 compared with $170 million in 2019, largely from the recognition of unrealized gains on securities. The non-GAAP effective income tax rates were 15.3% for the fourth quarter of 2020 and 15.5% for the full year of 2020. Non-GAAP EPS was $1.32 for the fourth quarter of 2020 compared with $1.16 for the fourth quarter of 2019. Non-GAAP EPS was $5.94 for the full year of 2020 compared with $5.19 for the full year of 2019. A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows. 11 2,580 5% 27% ISENTRESS / ISENTRESS HD % -5 7% 170 61 (UNAUDITED) 17 6 14% 62 RotaTeq 3,388 (2,094 255 (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company’s formal restructuring programs. KENILWORTH, N.J.–(BUSINESS WIRE)–Feb 4, 2021– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210204005437/en/ “Despite extraordinary challenges brought on by the COVID-19 pandemic, Merck achieved solid growth and made meaningful progress in our pipeline in 2020. We remain focused on our science-led strategy and are confident that this approach will continue to deliver value to patients and shareholders,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “Our scientists continue to advance our internal pipeline of promising medicines and vaccines, including in oncology, HIV, and pneumococcal disease, and, more recently, therapeutics for COVID-19. These pipeline developments provide us with increasing line-of-sight to significant potential growth drivers later this decade and into the next.” Financial Summary 180 (UNAUDITED) 8 (1.19 7,082 3,306 Certain OtherItems 2,789 Acquisition- andDivestiture-Related Costs3,4 9,843 1,087 (2 -28 47 58 1,609 Non-GAAP EPS that excludes items listed below 2 -8 56% ) -13 % Hospital Acute Care ) 37 Change 428 196 (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. 41 787 TAGS  11,868 1,609 59 13 97 (3,033 % 41,751 435 79 50 $1,855 101 ) 44 -19 2Q ChangeEx-Exchange Cost of sales Tax Rate 883 12% 11,367 2.78 247 80 63 10 38 72 Vaccines (3) -14 Full Year2020 ) 28% 69 194 -17% 64 70 67 -42 ) 194 7 − Selling, general and administrative -8 -23 472 -8 Cancidas 55 32 879 236 (3) (0.83 − 73 Sales 305 7 Research and development 2,648 370 $ 38 1 51 11,320 791 3,993 (2,092 7,067 ) 220 281 8 50 $ in millions, except EPS amounts ) 9,679 Restructuring costs (2) 1,131 205 5.94 $ 339 Lower than 2020 by a low-double-digit rate 82 4% * (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) 19.4 63 -61% -6% 7 Financial Outlook The guidance provided below is based on the assumption that the Organon business will be part of Merck for all of 2021; however, the Company expects that the Organon spinoff will occur late in the second quarter of 2021. If the spinoff occurs, these financial estimates will be updated. At mid-January 2021 exchange rates, Merck anticipates full-year 2021 revenue to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of approximately 2%. Merck expects full-year 2021 GAAP EPS to be between $5.52 and $5.72. Beginning in 2021, the Company will be changing the treatment of certain items for the purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded the amortization of intangible assets recognized in connection with business acquisitions but did not exclude the amortization of intangibles originating from collaborations, asset acquisitions or licensing arrangements. Beginning in 2021, Merck’s non-GAAP results will no longer differentiate between the nature of the intangible assets being amortized and will exclude all amortization of intangible assets. Also, beginning in 2021, Merck’s non-GAAP results will exclude gains and losses on investments in equity securities. On this new basis, Merck expects full-year 2021 non-GAAP EPS to be between $6.48 and $6.68, including an approximately 3% positive impact from foreign exchange. The non-GAAP range also excludes acquisition- and divestiture-related costs and costs related to restructuring programs. The changes to non-GAAP reporting resulted in a positive impact to projected 2021 non-GAAP EPS of approximately $0.08. For comparative purposes, Merck’s non-GAAP EPS in 2020 would have been $5.79 if reported under the new basis. The full-year guidance includes Merck’s current assumption of the impact from the COVID-19 pandemic. Merck projects strong underlying business growth for 2021. This growth is partially offset by the anticipated continuing impacts of the pandemic into 2021. Merck believes that global health systems and patients have largely adapted to the impacts of COVID-19 disease, but the company’s assumption is that ongoing residual negative impacts will persist, particularly during the first half of 2021 and most notably with respect to vaccine sales, which are expected to be more acute in the United States. For full-year 2021, Merck assumes an unfavorable impact to revenue of approximately 2% due to the COVID-19 pandemic, all of which relates to pharmaceutical segment sales. For full-year 2021, with respect to the COVID-19 pandemic, Merck expects a net negative impact on operating expenses, as spending on the development of its COVID-19 antiviral programs is expected to exceed the favorable impact of lower spending in other areas due to the COVID-19 pandemic. Neither the sales nor the EPS guidance ranges provided above include the impact of the potential launches of Merck’s COVID-19 antiviral drug candidates. The following table summarizes the company’s full-year 2021 financial guidance. 19 245 5,838 27 1,764 215 121 65 $1.32 Other (income) expense, net (1) 79 Immunology ) − (253 1,103 1,203 (2,094 -70 39 203 (UNAUDITED) 830 206 -5 ) -36 $2,718 Acquisition-related intangible asset impairment charges 4 2.78 126 $14,112 36 Companion Animals 92 1 313 Cardiovascular 194 -11 1.32 -20% 223 1,087 334 Non-GAAP2 166 9,486 33 % $6.48 to $6.68 309 145 306 Net decrease (increase) in income before taxes Costs, Expenses and Other -2 105 Average Shares Outstanding Assuming Dilution (3) Isentress / Isentress HD $2,440 838 444 9,231 53 391 $47,994 222 10 Full Year 28 -6 -12 807 559 77 83 1,687 9,663 167 2,153 108 Neuroscience 256 6% -32 45 Zerbaxa (37) 327 6 $12,057 137 98 15,485 -56 17% (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. 680 Dec. 31,2020 Singulair 1,122 10,655 -20 $ % 4% Change -22% 43 182 2% 30 57 (Loss) Earnings per Common Share Assuming Dilution (3) Fourth Quarter 9,070 51 1 -34 (360) 122 BRIDION 111 65 44 94 92 Income Tax Provision (Benefit) 205 1% $12,397 79 $13,382 145 Alliance Revenue – Adempas (4) 53 -55 83 Belsomra 81 % 124 67 4,615 8 54 260 28 38 Adempas (5) 31 ) ) 2,843 1,122 $51.8 to $53.8 billion* 53 Merck and AstraZeneca announced three approvals of Lynparza in Japan for:Maintenance treatment after first-line chemotherapy containing bevacizumab (genetical recombination) in patients with HRD ovarian cancer;Treatment of patients with BRCA gene-mutated ( BRCA m) castration-resistant prostate cancer with distant metastasis; andMaintenance treatment after platinum-based chemotherapy for patients with BRCA m curatively unresectable pancreas cancer. (506 Charges for the formation of collaborations 5 % 857 -11 − Diabetes (6) Januvia -4 $(0.83) 794 Oncology 180 227 Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. 170 943 -22 − -45 44% 9,872 57 4,703 − NuvaRing 44 (3 475 $3.81 (66 51 − Twitter 50 99 53 442 26 ) 124 Less: Net Income (Loss) Attributable to Noncontrolling Interests (1) 1,187 334 199 108 ) 165 $90 (3 Charge for the discontinuation of COVID-19 vaccine development programs 18% -13 -2 12,332 284 58 Tax Rate (4) -26 219 240 $3,539 179 $3,669 MERCK & CO., INC. 8% ) Certain OtherItems -50 (8,015 (800) 41% 43 % -7 191 79 − 224 7,067 -73 51 − 77 158 Table 2a -22 5,524 13 (1,993 (1) Only select products are shown. Pharmaceutical -12% Pinterest 2,364 -14 $11,868 Research and development ) ) (258) 486 10,533 54 FOURTH QUARTER 2020 15,082 -19 ) 263 288 56 -54 (0.32 Non-GAAP EPS that excludes certain items 2 ** 13% 94 Restructuring costs 152 278 -36 96 223 67 FULL YEAR 2020 FRANCHISE / KEY PRODUCT SALES 121 6 590 638 14.7 128 215 14,380 57 193 ) 61 -3 (1,993 725 656 109 -20 -5 ) Change Ex-Exchange 80 32 5 4,656 4,243 (9,070 309 (886 57 ) 854 $− $3,350 (4) Amount included in cost of sales represents a charge for the discontinuation of COVID-19 vaccine development programs. Amount included in research and development represents the charges for the acquisitions of VelosBio Inc. and OncoImmune, a charge for the discontinuation of COVID-19 vaccine development programs, and upfront payments related to license and collaboration agreements. MERCK & CO., INC. 3,938 1,220 206 Vytorin 578 1,124 5,444 47,994 10 17% (22 5.19 10 250 3,938 44% 191 $9,843 15.3 611 $ 16 2 481 2 2,764 2019 Net (Loss) Income 15,082 111 3,352 975 57 -2 11 453 396 3,086 3,111 Restructuring costs Zepatier 4,393 ) ) 188 98 26 $12,514 (Loss) Income Before Taxes 82 3,070 65 213 $ ) 2,660 -61 3,482 Sum of quarterly amounts may not equal year-to-date amounts due to rounding. $− (1,730 (802 3,957 309 2,041 Gardasil / Gardasil 9 76 15 284 Facebook 10 51 -32 Previous articleNuStar Energy L.P. Reports Fourth Quarter and Full-Year 2020 Earnings ResultsNext articleThis year’s Giro d’Italia to start in Turin on May 8 Digital AIM Web Supportlast_img read more

Man due in court following West Donegal fire

first_img Previous articleWater supplies could be curtailed as IW launches conservation appealNext articlePolice officers slightly injured in Derry car chase News Highland Loganair’s new Derry – Liverpool air service takes off from CODA News, Sport and Obituaries on Monday May 24th Google+ Facebook Pinterest Arranmore progress and potential flagged as population grows WhatsApp Nine til Noon Show – Listen back to Monday’s Programme Pinterest Important message for people attending LUH’s INR clinic Google+center_img Twitter Gardaí have arrested and charged a man  in his 50s, following a reported arson incident which led to a gorse fire in the Loughanoran area of Annagry yesterday.The fire began at approximately 12:30pm.Gardaí received reports of a man starting a fire outside a property in the area which then spread. Gardaí and Fire Services attended the scene. A technical examination of the area was carried out. No injuries were sustained as a result of this incident.The man was taken to Milford Garda Station, and is due beforer a special sitting of Dungloe District Court. Facebook Community Enhancement Programme open for applications Twitter Man due in court following West Donegal fire WhatsApp By News Highland – May 12, 2020 RELATED ARTICLESMORE FROM AUTHOR Homepage BannerNewslast_img read more

Storm Erik: Met Eireann upgrade weather warning for Donegal

first_imgA status orange wind warning has been issued for parts of the West coast as Storm Erik approaches Ireland. Met Éireann is warning of gusts of up to 130 kilometres an hour in counties Donegal, Galway and Mayo from tomorrow morning.While the rest of the country will be under a status yellow wind warning from 5am.High seas and coastal flooding are also expected. Storm Erik: Met Eireann upgrade weather warning for Donegal Pinterest Previous articleAlmost €680,000 approved for LIS schemes in DonegalNext articleMoville CC return to Senior Schools Girls Final News Highland Facebook Pinterest Twitter Important message for people attending LUH’s INR clinic WhatsApp Facebook Nine til Noon Show – Listen back to Monday’s Programme By News Highland – February 7, 2019 center_img RELATED ARTICLESMORE FROM AUTHOR Twitter Google+ Homepage BannerNews News, Sport and Obituaries on Monday May 24th Arranmore progress and potential flagged as population grows Google+ Loganair’s new Derry – Liverpool air service takes off from CODA WhatsApp Community Enhancement Programme open for applicationslast_img read more

Organisational risk of the Peter Principle

first_imgRelated posts:No related photos. Read full article Previous Article Next Article Organisational risk of the Peter PrincipleShared from missc on 9 Dec 2014 in Personnel Todaycenter_img The Peter Principle is a concept inwhich the selection of a candidate for a position is based on their performance in their current role rather than on their abilities relevant to the intended role. The business then of course running the risk of promoting someone until they are in a role in which they under-perform. How do we avoid this?From an HR perspective, the risk associated with the Peter Principle can be negated simply taking on-board the direction that an employee wishes to take their career, as opposed to promoting a staff member according to the company organisational structure only. Of course this doesn’t mean that we place less importance on the business objectives, because of course these are very important also – What it does mean that we should be using far more foresight when hiring and aiming to align someone’s key professional growth objectives with the organisational goals as much as possible.When we align an employee’s growth plan with organisational objectives, both parties stand to reap the benefits and in turn minimise risk. The employee is given the opportunity to achieve their professional goals and grow their knowledge and experience in the areas that the business requires that skill/experience which of course limits the likelihood of poor performance.Recruitment needs to become less reactionary (where possible) and more forward thinking and strategic. In doing so, employees will note that you have their best interests in mind along with other commercial interests, and this in turn – in most cases, will be reciprocated in the form of staff being engaged, driven and committed to achievement, all whilst managing potential future risk. Comments are closed.last_img read more